Journal of Publication

The BSRBRs have been publishing academic output for nearly fifteen years. Below are the published academic papers categorised by Journal of publication.


The Registers' systematic collection and analysis of large amounts of patient data traces the effects of biologics drugs in long term use. In addition, a large number of poster and oral presentations have also been given in the UK, Europe and internationally. The majority of these papers are from the RA Register. The AS register is far younger and its data is still maturing.


Thousands of people - patients, health professionals, managers, administrators and pharmaceutical sponsors have all contributed to creating this output. BSR is proud to be part of that partnership.

Most of the papers are available for FREE via open access. A 'DOI' - Digital Object Identifier - has been included to help locate the paper, simply copy and paste 'DOI' + its number as listed into the URL address bar and tap return. One of the top items will almost certainly link you directly to the paper you want.

Below are the Journals 


Rheumatology | Annals of the Rheumatic Diseases | Arthritis and Rheumatology | Arthritis Care Research | Arthritis Research and Therapy | BMC Musculoskeletal Disorders | Health and Quality of Life Outcomes | Musculoskeletal Care | Quality of Life Research | Journal of Biopharmaceutical Statistics | Journal of Rheumatology | American Journal of Epidemiology |




Rheumatology

Does sex or ethnicity impact anti-tumour necrosis factor agent use in rheumatoid arthritis?
Elaine M Dennison, Karen A Jameson, Jonathan Marks, Kath Watson, Kimme Hyrich, Deborah Symmons and Cyrus Cooper. [LETTER] Rheumatology (2016) doi: 10.1093/rheumatology/kew466

Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
K L Druce et al 2016 Rheumatology (2016) doi: 10.1093/rheumatology/kew241 First published online: June 21

Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor α: results from BSR's Biologics Register for Rheumatoid Arthritis Ellen S Bruce et al 2016 [LETTER] Rheumatology published 26 April 2016, 10.1093/rheumatology/kew200

The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers
Kearsley-Fleet L et al 2015 Rheumatology (Oxford).2015 Jun;54(6):1074-9. doi: 10.1093/rheumatology/keu446.

The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era.
Morgan C et al 2015 Rheumatology (Oxford). 2015 May 13. pii: kev105. [Epub ahead of print] 

Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis Druce KL et al 2015 Rheumatology (2015) 54 (6): 964-971 doi:10.1093/rheumatology/keu390

Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying ant-rheumatic drugs: long-term safety and survival using prospective observational data
Morgan CL et al 2014 Rheumatology (Oxford), 53(1), 186-94 doi: 10.1093/rheumatology/ket333

Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register.
McErlane F et al 2013 Rheumatology (Oxford), 52(10), 1905-1913. DOI:10.1093/rheumatology/ket248

Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population.
Mercer L et al 2013 Rheumatology (Oxford), 52(1), 91-98. DOI:10.1093/rheumatology/kes350

The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Galloway JB et al 2011 Rheumatology, 50(7), 1341-1342. DOI:10.1093/rheumatology/ker146

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.
Galloway J et al 2011 Rheumatology (Oxford), 50(1), 124-131. DOI:10.1093/rheumatology/keq242

Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008.
Hyrich K et al 2011 Rheumatology (Oxford), 50(1), 117-123. DOI:10.1093/rheumatology/keq209

Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers.
Strangfeld A et al 2011 Rheumatology (Oxford), 50(1), 146-151. DOI:10.1093/rheumatology/keq301

Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.
Lord P et al 2010 Rheumatology (Oxford), 49(3), 563-567. DOI:10.1093/rheumatology/kep422

Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register.
Saad A et al 2010 Rheumatology (Oxford), 49(4), 697-705. DOI:10.1093/rheumatology/kep423

Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.
Verstappen S et al 2010 Rheumatology, 49(8), 1570-1577. DOI:10.1093/rheumatology/keq131

Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity.
Hyrich K et al 2009 Rheumatology (Oxford), 48(10), 1323-7. DOI:10.1093/rheumatology/kep242

Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.
Hyrich KL et al 2008 Rheumatology (Oxford), 47( 7), 1000-5.

The British Society for Rheumatology Biologics Register: 6 years on
Hyrich KL et al 2008 Rheumatology (Oxford), 47(10) 1441-3 DOI 10.1093/rheumatology/ken242

Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
Brennan A et al 2007 Rheumatology (Oxford), 46(8), 1345-54. doi: 10.1093/rheumatology/kem115

Predictors of response to anti-TNF-{alpha} therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL et al 2006 Rheumatology, 45, 12, 1558-1565. DOI:10.1093/rheumatology/kel149

UK Consultant Rheumatologists' access to biological agents and views on the BSR Biologics Register.
Kay LJ et al 2006 Rheumatology (Oxford) 45(11) 1376-9 doi:10.1093/rheumatology/kel333

 

Back to top


Annals of the Rheumatic Diseases

 

Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis

Audrey SL Low, Deborah P M Symmons, Mark Lunt, Louise K Mercer, Chris P Gale,Kath D Watson, William G Dixon, Kimme L Hyrich, on behalf of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBRRA) and the BSRBR Control Centre Consortium. Ann Rheum Dis Published Online First: 10 January 2017 doi:10.1136/annrheumdis-2016-209784


Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.
LK Mercer et al 2016 Ann Rheum Dis Published Online First: 15 June 2016 doi:10.1136/annrheumdis-2016-209285

Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Mercer L et al. 2014 Ann Rheum Dis [Epub ahead of print], DOI:10.1136/annrheumdis-2013-20485

The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA.
Závada J et al 2014 Ann Rheum Dis 73(1), 252-255. DOI:10.1136/annrheumdis-2012-20310

Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Galloway J et al 2013 Ann Rheum Dis 72(2), 229-234. DOI:10.1136/annrheumdis-2011-201108

Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix.
Mercer L et al 2013 Ann Rheum Dis 72(1), 143-144. DOI:10.1136/annrheumdis-2012-201814

The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.
Mercer, L. et al. 2012 Annals of the rheumatic diseases, 71(6), 869-874. DOI:10.1136/annrheumdis-2011-200622

Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. 
Davies R et al  2011 Ann Rheum Dis, 70(10), 1831-4. DOI:10.1136/ard.2011.153536

Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.
Galloway, J. et al 2011 Ann Rheum Dis, 70(10), 1810-1814. DOI:10.1136/ard.2011.152769

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Soliman M et al 2011 Annals of the rheumatic diseases, 70(4), 583-589. DOI:10.1136/ard.2010.139774

Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register.
Verstappen S et al 2011 Annals of the rheumatic diseases, 70(5), 823-826. DOI:10.1136/ard.2010.140822

Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.
Dixon W et al 2010 Annals of the rheumatic diseases, 69(6), 1086-1091. DOI:10.1136/ard.2009.120626

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).
Dixon W et al 2010 Annals of the rheumatic diseases, 69(3), 522. DOI:10.1136/ard.2009.118935

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-TNF{alpha} therapy.
Harrison MJ et al 2009 Ann Rheum Dis, 68(2), 209-215. DOI:10.1136/ard.2007.087288

Baseline Comorbidity Levels in Biologic and Standard DMARD Treated Patients with Rheumatoid Arthritis: Results from a National Patient Register. 
Hyrich KL et al 2006 Annals of the Rheumatic Diseases, 65, 7, 895-898. doi:10.1136/ard.2005.043158

The British Society for Rheumatology biologics register.  
Watson K et al 2005 Ann Rheum Dis, 64 Suppl 4, iv42-3. DOI:10.1136/ard.2005.042499

Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.
Hyrich K et al 2004 Ann Rheum Dis, 63(12), 1538-43. DOI:10.1136/ard.2004.024737

British Society for Rheumatology Biologics Register.
Silman A et al 2003 Ann Rheum Dis, 62 Suppl 2, ii28-9. DOI:10.1136/ard.62.suppl. 2.ii28 

Back to top


Arthritis and Rheumatology

 

Association between ischaemic stroke and tumor necrosis factor inhibitor therapy in patients with
rheumatoid arthritis.
Audrey SL Low et al 2016 Arthritis & Rheumatology accepted article DOI 10.1002/art.39582

Determining pathways to improvements in fatigue in Rheumatoid Arthritis - Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Druce KL et al 2015 Arthritis & Rheumatology Vol. 67, No. 9, September 2015, pp 2303–2310 [Epub ahead of print] DOI 10.1002/art.39238 

Genome-wide association study of genetic predictors of anti-tumour necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. 
Plant D et  al. 2011 Arthritis Rheum, 63(3) 645-53 DOI 10.1002/art.30130

No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register.
Lunt M et al 2010 Arthritis and Rheumatism, 62(11), 3145-3153. DOI:10.1002/art.27660

Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.
Dixon WG et al 2007 Arthritis Rheum, 56( 9), 2896-904. DOI: 10.1002/art.22808

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. 
Dixon WG et al 2007 Arthritis Rheum, 56( 9), 2905-12. DOI: 10.1002/art.22809

Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
Hyrich KL et al 2007 Arthritis Rheum, 56( 1), 13-20. DOI:10.1002/art.22331

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register.
Dixon WG et al 2006 Arthritis and Rheumatism, 54, 8, 2368-2376. DOI:10.1002/art.21978

Comparison of the response to infliximab or etanercept monotherapy with the response to co-therapy with methotrexate or another disease-modifying anti-rheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register.
Hyrich KL et al 2006 Arthritis and Rheumatism, 54, 6, 1786-1794. DOI: 10.1002/art.21830

Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: Results from a national population register. 
Hyrich KL et al 2006 Arthritis and Rheumatism, 54, 8, 2701-2702. DOI: 10.1002/art.22028

 

Back to top


Arthritis Care Research

 

The changes in pain which mediate reductions in fatigue likely reflect central not peripheral mechanisms. Results from the BSRBR-RA KL
Druce et al 2015 Arthritis Care and Research 25 Nov 2015 DOI:10.1002/acr.22803.

Rituximab or a second anti-TNF therapy for rheumatoid arthritis patients who have failed their first anti-TNF? Comparative analysis from the British Society for Rheumatology Biologics Register.
Soliman M et al 2012 Arthritis Care Res (Hoboken), 64(8), 1108-1115. DOI:10.1002/acr.21663

Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for Rheumatology Biologics Register. 
Dixon W et al 2010 Arthritis Care Res (Hoboken), 62(6), 755-63. DOI:10.1002/acr.20129

Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies.
Saad A et al 2010 Arthritis Care Res (Hoboken), 62(3), 345-53. DOI:10.1002/acr.20104

 

Back to top


Arthritis Research and Therapy

 

Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register.
Saad AA et al 2009 Arthritis Res Ther, 11(2), R52. DOI:10.1186/ar2670

 

Back to top


BMC Musculoskeletal Disorders

 

Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
Daniel F. McWilliams and David A. Walsh BMC Musculoskeletal Disorders  (2016) 17:337  DOI 10.1186/s12891-016-1192-7

The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologics treatment.
Gary J. Macfarlane et al 2015 BMC Musculoskeletal Disorders (2015) 16: 347 DOI 10.1186/s12891-015-0805-x

 

Back to top


Health and Quality of Life Outcomes

 

Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis.
Harrison M et al 2010 Health Qual Life Outcomes, 8(1), 21. DOI:10.1186/1477-7525-8-21

 

Back to top


Musculoskeletal Care

 

The role of the British Society for Rheumatology Biologics Register (BSRBR) and the NICE guidelines for anti-TNF therapy.
Watson K et al 003 Musculoskeletal Care 2003 1(1) 58-64 DOI:10.1002/msc.39

 

Back to top


Quality of Life Research

 

The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis.
Harrison MJ et al 2009 Qual Life Res. 18(9) 1195-1205

 

Back to top


Journal of Biopharmaceutical Statistics

 

A threshold hazard model for estimating serious infection risk following anti-tumor necrosis factor therapy in rheumatoid arthritis patients. Fu B et al
2013 J Biopharm Stat, 23(2), 461-76. DOI:10.1080/10543406.2011.616973

 

Back to top


Journal of Rheumatology

 

Effectiveness of Rituximab in Patients with Rheumatoid Arthritis: Observational Study from the British Society for Rheumatology Biologics Register.
Soliman M et al  2012 J Rheumatol, 39(2), 240-246. DOI:10.3899/jrheum.110610

 

Back to top


American Journal of Epidemiology

 

Different Methods of Balancing Covariates Leading to Different Effect Estimates in the Presence of Effect Modification.
Lunt M et al  2009 American Journal of Epidemiology, 169(7), 909-917. DOI:10.1093/aje/kwn391
 

 
Back to top